Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | ELANE | P08246 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GGT1 | P19440 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16756220 | 0.91 | ESR1 (0.66) | ESR1ESR2POLBELANEKMT2A | |
| SCHEMBL10571601 | 0.91 | ESR1 (0.66) | ESR1ESR2POLBELANEKMT2A | |
| SCHEMBL16756210 | 0.91 | ESR1 (0.66) | ESR1ESR2POLBELANEKMT2A | |
| SCHEMBL16756223 | 0.89 | ESR1 (0.63) | ESR1ESR2POLBELANEKMT2A | |
| SCHEMBL31321646 | 0.87 | POLB (0.62) | ESR1ESR2POLBELANEKMT2A | |
| SCHEMBL16756229 | 0.86 | KMT2A (0.64) | ESR1ESR2POLBELANEKMT2A | |
| SCHEMBL7316979 | 0.84 | L3MBTL1 (0.49) | ESR1ESR2POLBELANEKMT2A | |
| SCHEMBL11590449 | 0.83 | ESR1 (0.57) | ESR1ESR2POLBELANEKMT2A | |
| SCHEMBL31321655 | 0.83 | HPGD (0.54) | ESR1ESR2POLBELANEKMT2A | |
| SCHEMBL16756212 | 0.82 | L3MBTL1 (0.70) | ESR1ESR2POLBELANEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468464-B2 | Resorcinol derivatives for skin | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1861353-B1 | NOVEL RESORCINOL DERIVATIVES FOR SKIN | UNILEVER PLC (GB) | 2008-10-08 | — | — | EP | disclosed |
| US-20080131382-A1 | Novel Resorcinol Derivatives for Skin | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1861353-A1 | NOVEL RESORCINOL DERIVATIVES FOR SKIN | UNILEVER PLC (GB) | 2007-12-05 | — | — | EP | disclosed |
| US-20060210498-A1 | Novel resorcinol derivatives for skin | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006097224-A1 | NOVEL RESORCINOL DERIVATIVES FOR SKIN | UNILEVER PLC (GB) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080131382-A1 | Novel Resorcinol Derivatives for Skin | NR1H2, CYP1B1, NR0B1 | ESR1 1097/4885ESR2 1020/4885POLB 920/4885 |
| US-20060210498-A1 | Novel resorcinol derivatives for skin | NR1H2, CYP1B1, NR0B1 | ESR1 1097/4885ESR2 1020/4885POLB 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.